Factor XII Inhibitors Market Report 2026

The factor xii inhibitors market size has grown rapidly in recent years. It will grow from $1.4 billion in 2025 to $1.55 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to advancements in coagulation biology research, increasing incidence of thrombotic disorders, limitations of traditional anticoagulants, early-stage clinical success of fxii inhibition, growing investment in rare and specialty therapeutics.

The factor xii inhibitors market size is expected to see rapid growth in the next few years. It will grow to $2.34 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to expansion of late-stage clinical trials, increasing demand for safer antithrombotic therapies, rising precision medicine adoption, growing regulatory support for novel anticoagulants, expansion of fxii inhibitors into inflammatory indications. Major trends in the forecast period include increasing development of non-bleeding anticoagulant therapies, rising focus on targeted coagulation pathway modulation, growing clinical evaluation of fxii selective inhibitors, expansion of rna-based and peptide therapeutics, enhanced use of precision drug design.

The increasing prevalence of thrombotic disorders is anticipated to drive expansion in the factor XII inhibitors market. Thromboembolic disorders occur when blood clots develop in veins or arteries, which can obstruct blood flow and lead to severe health issues. These disorders are on the rise due to growing sedentary lifestyles that impair blood circulation and elevate clot risks. Factor XII inhibitors address thrombotic disorders by inhibiting the contact activation pathway to prevent excessive clotting, while preserving normal hemostasis. This approach enables thrombosis management with reduced bleeding risks. For instance, in January 2025, the Centers for Disease Control and Prevention (CDC), a US government agency, reported that about 900,000 people in the United States experience venous thromboembolism annually, with 60,000-100,000 deaths and many facing lasting complications. Thus, the growing incidence of thrombotic disorders is fueling the Factor XII inhibitors market.

The growing emphasis on targeted therapies is poised to accelerate the expansion of the factor XII inhibitors market in the future. Targeted therapies represent treatments that precisely target and block molecular irregularities in cancer or other conditions, enhancing treatment accuracy while reducing damage to healthy cells. This heightened focus stems mainly from progress in precision medicine, which supports customized, more potent interventions tailored to patients' unique genetic makeup. Factor XII inhibitors bolster targeted therapies by selectively regulating the intrinsic coagulation pathway, positioning them as optimal for individuals prone to thrombotic issues. Unlike traditional anticoagulants, they lower bleeding risks through targeted Factor XII inhibition, thereby boosting overall safety and effectiveness. For example, in December 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit dedicated to medical and scientific advancement, reported that the Food and Drug Administration (FDA) greenlit 6 gene therapy products in 2023, compared to 5 in 2022. Thus, the rising emphasis on targeted therapies is fueling the factor XII inhibitors market's growth.

Major companies in the Factor XII Inhibitors market are prioritizing the development of cutting-edge products, like anti-FXIIa monoclonal antibodies, to improve therapeutic accuracy and efficacy. These anti-FXIIa monoclonal antibodies function as targeted biologics that block activated factor XII, halting excessive clot formation while maintaining normal hemostasis. For example, in February 2025, CSL Behring GmbH - a biopharmaceutical firm based in Germany - secured manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY (garadacimab) subcutaneous (S.C.) injection 200 mg pens. This innovative human anti-activated factor XII monoclonal antibody is approved for preventing acute attacks of hereditary angioedema (HAE). It targets activated factor XIIa, a primary trigger for HAE attacks, and is delivered through a user-friendly subcutaneous injection pen.

Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC.

North America was the largest region in the factor XII inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xii inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the factor xii inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the factor xii inhibitors market by increasing costs of imported active pharmaceutical ingredients, biologic raw materials, specialized reagents, and advanced manufacturing equipment used in monoclonal antibody and small molecule production. North America and Europe are most affected due to dependence on cross-border sourcing of high-purity biologics and clinical-grade compounds, while Asia-Pacific faces cost pressure in contract manufacturing and clinical trial supply chains. These tariffs are raising development and production costs and extending commercialization timelines. However, they are also encouraging localized drug manufacturing, regional API production, and strategic partnerships to strengthen domestic pharmaceutical supply resilience.

The factor xii inhibitors market research report is one of a series of new reports that provides factor xii inhibitors market statistics, including factor xii inhibitors industry global market size, regional shares, competitors with a factor xii inhibitors market share, detailed factor xii inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the factor xii inhibitors industry. This factor xii inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Factor XII inhibitors are drugs that inhibit the function of coagulation Factor XII, a protein responsible for starting the intrinsic pathway of blood clotting. They halt the activation of subsequent clotting mechanisms while having minimal impact on normal hemostasis. Their main goal is to decrease pathological thrombosis and related clotting issues, providing a reduced risk of bleeding relative to conventional anticoagulants.

The primary categories of Factor XII inhibitors include monoclonal antibodies, small molecule inhibitors, and additional types. Monoclonal antibodies, which are engineered in labs, precisely target Factor XII to halt excessive blood clotting while posing a low risk of bleeding. They are delivered via oral, injectable, or alternative methods. These medications treat conditions like hereditary angioedema, thrombosis, inflammatory diseases, and more, benefiting end-users such as hospitals, specialty clinics, research facilities, and others.

The factor XII inhibitors market consists of revenues earned by entities by providing services such as formulation development, drug delivery optimization, laboratory testing, diagnostic support, regulatory consulting, pharmacovigilance, and contract manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The factor XII inhibitors market also includes sales of anticoagulant formulations, combination therapies, diagnostic kits, research reagents, laboratory consumables, and supportive medical devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.